Chimerix Inc CMRX

NAS: CMRX | ISIN: US16934W1062 2/06/2023

1,450 USD (+4,32%)

(+4,32%) 2/06/2023

Toon enkel gratis nieuws

2 maart 2021 · Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference · Persbericht

26 februari 2021 · Chimerix, Exclusive Worldwide Licensee of Cantex's Investigational Product, DSTAT, Has Announced Promising Topline Results from the First Cohort of a Randomized COVID-19 Clinical Trial · Persbericht

25 januari 2021 · Chimerix Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares · Persbericht

21 januari 2021 · Chimerix Announces Pricing of Public Offering of Common Stock · Persbericht

19 januari 2021 · Chimerix Announces Proposed $75,000,000 Public Offering of Common Stock · Persbericht

8 januari 2021 · Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe